Sandoz Archives | Be Korea-savvy
Home / Posts tagged Sandoz
Sandoz Signs Non-binding Term Sheet with Evotec SE to Acquire Its Just-Evotec Biologics In-house Development and Manufacturing Capabilities in Toulouse, France

Sandoz Signs Non-binding Term Sheet with Evotec SE to Acquire Its Just-Evotec Biologics In-house Development and Manufacturing Capabilities in Toulouse, France

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1] Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility Sandoz would acquire Just-Evotec [...]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio Builds on established experience and leadership in oncology and immunology [...]

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade ago, etanercept biosimilar continues to be blocked Sandoz seeking damages in addition to clearing path for launch Basel, April [...]

Francisco Ballester to retire; Peter Stenico appointed President Region International

Francisco Ballester to retire; Peter Stenico appointed President Region International

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service Peter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, concurrently appointed President Region International and a member of the Sandoz Executive Committee Basel, [...]

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025 Ambitious GLP-1 strategy in [...]

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz US has entered into a settlement agreement with the class of end payer plaintiffs for USD 275 million Provision of USD 265 million taken to cover potential additional settlement costs with regard to the US generic drug industry antitrust litigation No impact on [...]

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced [...]

Sandoz Receives FDA Approval for Enzeevu™ (aflibercept-abzv), Further Strengthening US Biosimilar Position

Sandoz Receives FDA Approval for Enzeevu™ (aflibercept-abzv), Further Strengthening US Biosimilar Position

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalmology portfolio and increases access for patients Expected to be key biosimilar growth driver in US Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, [...]

Sandoz Reports Second-quarter Sales and Half-year 2024 Results

Sandoz Reports Second-quarter Sales and Half-year 2024 Results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD) Half-year net sales of USD 5.0 billion, up 7% in constant currencies [...]